This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Other skin disorders
  • /
  • Secukinumab, a fully human anti-interleukin-17A mo...
Journal

Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis,

Read time: 1 mins
Published:22nd Nov 2016
Author: Reich K, Blauvelt A, Armstrong A, Langley RG, Fox T, Huang J, Papavassilis C, Liang E, Lloyd P, Bruin G.
Availability: Pay for access, or by subscription
Ref.:Br J Dermatol. 2017 Mar;176(3):752-758.
DOI: 10.1111/bjd.14965.
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest